中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
2期
188-192
,共5页
脑梗死%普罗布考%血清抵抗素%血脂
腦梗死%普囉佈攷%血清牴抗素%血脂
뇌경사%보라포고%혈청저항소%혈지
Cerebral infarction%Probucol%Serum resistin%Blood lipid
目的 探讨普罗布考对急性动脉粥样硬化性脑梗死患者血清抵抗素及血脂水平的影响.方法 选取2012年4月至2013年4月在山东省高密市人民医院神经内科住院治疗的急性动脉粥样硬化性脑梗死患者102例,采用最小随机化法将入组者分为常规治疗组(51例)与联合治疗组(51例).常规治疗组给予他汀类药物和抗血小板聚集药物.联合治疗组在常规治疗组基础上加用普岁布考.2组患者均在治疗前和治疗后14 d清晨采集空腹静脉血检测血清抵抗素、总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇水平,采用改良爱丁堡-斯勘的那维亚卒中量表评价患者神经功能,比较2组患者治疗前和治疗后14 d的血清抵抗素、血脂水平及治疗前、治疗后7 d、治疗后14d的神经功能评分.结果 治疗后14 d,联合治疗组患者血清抵抗素水平[(17±9) mg/L]低于治疗前[(24±9) mg/L]和常规治疗组[(23±9) mg/L];总胆固醇水平[(4.0±1.0)mmol/L]低于治疗前[(5.0±1.0)mmol/L];LDL-C水平[(2.3±0.8)mmol/L]低于治疗前[(3.3±0.8)mmol/L和常规治疗组[(2.8±1.0) mmol/L];神经功能评分[(8.0±3.2)分]低于治疗前[(25.0±2.9)分]和常规治疗组[(13.2±2.5)分],差异均有统计学意义(均P ＜0.05).结论 普罗布考联合他汀类药物治疗能够改善急性动脉粥样硬化性脑梗死患者血清抵抗素及血脂水平,提高患者近期疗效.
目的 探討普囉佈攷對急性動脈粥樣硬化性腦梗死患者血清牴抗素及血脂水平的影響.方法 選取2012年4月至2013年4月在山東省高密市人民醫院神經內科住院治療的急性動脈粥樣硬化性腦梗死患者102例,採用最小隨機化法將入組者分為常規治療組(51例)與聯閤治療組(51例).常規治療組給予他汀類藥物和抗血小闆聚集藥物.聯閤治療組在常規治療組基礎上加用普歲佈攷.2組患者均在治療前和治療後14 d清晨採集空腹靜脈血檢測血清牴抗素、總膽固醇、三酰甘油、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇水平,採用改良愛丁堡-斯勘的那維亞卒中量錶評價患者神經功能,比較2組患者治療前和治療後14 d的血清牴抗素、血脂水平及治療前、治療後7 d、治療後14d的神經功能評分.結果 治療後14 d,聯閤治療組患者血清牴抗素水平[(17±9) mg/L]低于治療前[(24±9) mg/L]和常規治療組[(23±9) mg/L];總膽固醇水平[(4.0±1.0)mmol/L]低于治療前[(5.0±1.0)mmol/L];LDL-C水平[(2.3±0.8)mmol/L]低于治療前[(3.3±0.8)mmol/L和常規治療組[(2.8±1.0) mmol/L];神經功能評分[(8.0±3.2)分]低于治療前[(25.0±2.9)分]和常規治療組[(13.2±2.5)分],差異均有統計學意義(均P ＜0.05).結論 普囉佈攷聯閤他汀類藥物治療能夠改善急性動脈粥樣硬化性腦梗死患者血清牴抗素及血脂水平,提高患者近期療效.
목적 탐토보라포고대급성동맥죽양경화성뇌경사환자혈청저항소급혈지수평적영향.방법 선취2012년4월지2013년4월재산동성고밀시인민의원신경내과주원치료적급성동맥죽양경화성뇌경사환자102례,채용최소수궤화법장입조자분위상규치료조(51례)여연합치료조(51례).상규치료조급여타정류약물화항혈소판취집약물.연합치료조재상규치료조기출상가용보세포고.2조환자균재치료전화치료후14 d청신채집공복정맥혈검측혈청저항소、총담고순、삼선감유、저밀도지단백담고순(LDL-C)、고밀도지단백담고순수평,채용개량애정보-사감적나유아졸중량표평개환자신경공능,비교2조환자치료전화치료후14 d적혈청저항소、혈지수평급치료전、치료후7 d、치료후14d적신경공능평분.결과 치료후14 d,연합치료조환자혈청저항소수평[(17±9) mg/L]저우치료전[(24±9) mg/L]화상규치료조[(23±9) mg/L];총담고순수평[(4.0±1.0)mmol/L]저우치료전[(5.0±1.0)mmol/L];LDL-C수평[(2.3±0.8)mmol/L]저우치료전[(3.3±0.8)mmol/L화상규치료조[(2.8±1.0) mmol/L];신경공능평분[(8.0±3.2)분]저우치료전[(25.0±2.9)분]화상규치료조[(13.2±2.5)분],차이균유통계학의의(균P ＜0.05).결론 보라포고연합타정류약물치료능구개선급성동맥죽양경화성뇌경사환자혈청저항소급혈지수평,제고환자근기료효.
Objective To investigate the effect of probucol on the levels of serum resistin and blood lipid in patients with acute cerebral infarction.Methods Totally 102 patients with acute cerebral infarction were collected from April 2012 to April 2013.The patients were randomly divided into two groups:conventional treatment group(51 cases) and combined treatment group (51 cases).At the first day and after two weeks,the fasting venous blood samples were collected for measuring serum resistin and total cholesterol,triacylglycerol,low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol.At 7 d and 14 d,curative effects were evaluated by standard scale of clinical neurological deficit.Results After the treatment,the level of serum resistin in combined treatment group[(17 ± 9)mg/L] was lower than that before treatment [(24 ± 9)mg/L] and that in the conventional treatment group [(23 ± 9)mg/L] ; the level of total cholesterol [(4.0 ± 1.0)mmol/L] was lower than that before treatment[(5.0 ± 1.0)mmol/L] ; the level of LDL-C [(2.3 ± 0.8)mmol/L] was lower than that before treatment[(3.3 ±0.8) mmol/L] and that in the conventional treatment group[(2.8 ± 1.0) mmol/L] ; neurological function score [(8.0 ± 3.2) points] was below than that before treatment [(25.0 ± 2.9) points] and that in routine treatment group[(13.2 ± 2.5) points] ; the differences were statistically significant (all P ＜ 0.05).Conclusion The treatment of probucol combining with statins can improve the level of serum resistin and blood lipid profile of patients with acute cerebral infarction.
